Bronshteĭn I B, Shuster A M, Gromova I I, Kvashchuk O A, Geva O N, Gololobov G V, Prokaeva T B, Alekberova Z S, Gabibov A G
Biull Eksp Biol Med. 1990 Dec;110(12):598-600.
The interaction of sera from 34 patients with different autoimmune diseases with the expressed fusion protein cloned in lambda gt11 vector (topoisomerase I--beta galactosidase) and monoclonal antibodies against enzyme was studied. It was demonstrated that 100% of Scl cases possessed positive activity against fusion protein. It was shown that this test is not absolutely specific for Scl, i. e. 57.1% of Sle and 84.6% of RA demonstrated positive activity against "topoisomerase test". Autoimmune sera had the positive activity against monoclonal antibodies for topoisomerase I. This activity was shown to be due to the presence of antiidiotypic antibodies against topoisomerase in the autoimmune sera.
研究了34例不同自身免疫性疾病患者的血清与克隆于λgt11载体的表达融合蛋白(拓扑异构酶I-β半乳糖苷酶)及抗该酶单克隆抗体的相互作用。结果表明,100%的硬皮病(Scl)病例对融合蛋白具有阳性活性。研究还表明,该检测对硬皮病并非绝对特异,即57.1%的系统性红斑狼疮(Sle)和84.6%的类风湿关节炎(RA)对“拓扑异构酶检测”呈阳性活性。自身免疫血清对拓扑异构酶I的单克隆抗体具有阳性活性。这种活性被证明是由于自身免疫血清中存在针对拓扑异构酶的抗独特型抗体。